NEW YORK, December 25, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Cigna Corp. (NYSE: CI), CareFusion Corporation (NYSE: CFN), Health Management Associates Inc. (NYSE: HMA), MiMedx Group, Inc. (NASDAQ: MDXG), and Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Cigna Corp. Research Report
On December 19, 2013, Cigna Corp. (Cigna) reported that the National Committee for Quality Assurance (NCQA), a private, non-profit organization dedicated to improving health care quality, has recognized its chronic condition support programs. Cigna stated that it has received NCQA Patient and Practitioner Oriented Disease Management (DM) Accreditation for asthma, chronic obstructive pulmonary disease, congestive heart failure, coronary artery disease, depression, and diabetes. The Company stated that earning NCQA DM Accreditation is an indication that a DM program is dedicated to giving patients and/or practitioners the support, education and other help necessary to facilitate good outcomes and good care. "Earning this NCQA accreditation demonstrates Cigna's commitment to improving the health, well-being and sense of security of our customers," said Michael Reardon, M.D., National Medical Director responsible for Cigna's chronic condition support programs. "Cigna's integrated, holistic approach to managing chronic conditions provides customers with multiple options to best meet their individual health care needs." The Full Research Report on Cigna Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
CareFusion Corporation Research Report
On December 20, 2013, CareFusion Corp.'s (CareFusion) stock declined slightly to end the day's trading session at $39.40, representing a 0.35% decline. The Company's stock rose at 2.36% over the past three-day trading period, compared to the Dow Jones Industrial Average Index which gained 2.18% over the same trading period. The Full Research Report on CareFusion Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Health Management Associates Inc. Research Report
On December 20, 2013, Health Management Associates Inc.'s (Health Management) stock gained 1.17% to end the day's trading session at $12.98. The Company's stock rose 0.39% over the past three trading days, compared to the Dow Jones Industrial Average Index which rose 2.18% over the same trading period. The Full Research Report on Health Management Associates Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
MiMedx Group, Inc. Research Report
On December 12, 2013, MiMedx Group, Inc. (MiMedx) announced that its wound care allograft, EpiFix®, has received reimbursement coverage from Medicare contractor, CGS. According to the Company, CGS' coverage brings the total Medicare Administrative Contractors (MACs) covering EpiFix® to six of the eight and 86% of Medicare beneficiaries will now be eligible for coverage for EpiFix® products. "We have been persistent in executing our strategy to gain MAC coverage throughout the country," said Parker H. Petit, Chairman and CEO of MiMedx. "With the additional coverage by CGS encompassing the states of Kentucky and Ohio, we have further expanded the opportunity for Medicare beneficiaries suffering from chronic wounds to have access to our clinically and cost effective allografts." The Full Research Report on MiMedx Group, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Merrimack Pharmaceuticals, Inc. Research Report
On December 20, 2013, Merrimack Pharmaceuticals, Inc. (Merrimack) announced that the Company's President and CEO, Robert Mulroy, will present at the 32nd Annual J.P. Morgan Healthcare Conference, on January 15, 2014, Wednesday at 3:00 p.m. PT at the Westin St. Francis Hotel in San Francisco. According to the Company, a live webcast of the presentation can be accessed by visiting the Investors section of Merrimack's website, wherein a replay of the same will be archived for two weeks following the presentation. The Full Research Report on Merrimack Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner